Compound E
						    			         
			    					
		(Synonyms: N-[(1S)-2-[[(3S)-2,3-二氢-1-甲基-2-氧代-5-苯基-1H-1,4-苯并二氮杂卓-3-基]氨基]-1-甲基-2-氧代乙基]-3,5-二氟苯乙酰胺,γ-Secretase-IN-1)		目录号 : GC33118
	An inhibitor of γ-
     
    
Cas No.:209986-17-4
Sample solution is provided at 25 µL, 10mM.
γ-
1.Jurisch-Yaksi, N., Sannerud, R., and Annaert, W.A fast growing spectrum of biological functions of γ-secretase in development and diseaseBiochim. Biophys. Acta1828(12)2815-2827(2013) 2.Seiffert, D., Bradley, J.D., Rominger, C.M., et al.Presenilin-1 and -2 are molecular targets for γ-secretase inhibitorsJ. Biol. Chem.275(44)34086-34091(2000) 3.Beher, D., Wrigley, J.D.J., Nadin, A., et al.Pharmacological knock-down of the presenilin 1 heterodimer by a novel g -secretase inhibitor. Implications for presenilin biologyJ. Biol. Chem.276(48)45394-45402(2001) 4.Zhao, G., Mao, G., Tan, J., et al.Identification of a new presenilin-dependent ζ-cleavage site within the transmembrane domain of amyloid precursor proteinJ. Biol. Chem.279(49)50647-50650(2004) 5.Ferrari-Toninelli, G., Bonini, S.A., Uberti, D., et al.Targeting Notch pathway induces growth inhibition and differentiation of neuroblastoma cellsNeuro. Oncol.12(12)1231-1243(2010) 6.Jovanovic, V.P., Sauer, C.M., Shawber, C.J., et al.Intraovarian regulation of gonadotropin-dependent folliculogenesis depends on notch receptor signaling pathways not involving Delta-like ligand 4 (Dll4)Reprod. Biol. Endocrinol.1143(2013) 7.Doerfler, P., Shearman, M.S., and Perlmutter, R.M.Presenilin-dependent γ-secretase activity modulates thymocyte developmentProc. Natl. Acad. Sci. USA98(16)9312-9317(2001)
| Cell experiment: | The breast cancer cell lines MDA-MB-231, T47D, and MCF-7 are treated with Compound E at concentrations in the range 0.01-50 μM for 48 h and their viability is determined using a Coulter counter[1]. | 
| References: [1]. Beher D, et al. Pharmacological knock-down of the presenilin 1 heterodimer by a novel gamma -secretase inhibitor: implications for presenilin biology. J Biol Chem. 2001 Nov 30;276(48):45394-402. | |
| Cas No. | 209986-17-4 | SDF | |
| 别名 | N-[(1S)-2-[[(3S)-2,3-二氢-1-甲基-2-氧代-5-苯基-1H-1,4-苯并二氮杂卓-3-基]氨基]-1-甲基-2-氧代乙基]-3,5-二氟苯乙酰胺,γ-Secretase-IN-1 | ||
| Canonical SMILES | FC1=CC(CC(N[C@@H](C)C(N[C@@H]2C(N(C)C(C=CC=C3)=C3C(C4=CC=CC=C4)=N2)=O)=O)=O)=CC(F)=C1 | ||
| 分子式 | C27H24F2N4O3 | 分子量 | 490.5 | 
| 溶解度 | DMSO: 100 mg/mL (203.87 mM) | 储存条件 | Store at -20°C, sealed storage, away from moisture and light | 
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 | ||
| Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
|  | 1 mg | 5 mg | 10 mg | 
| 1 mM | 2.0387 mL | 10.1937 mL | 20.3874 mL | 
| 5 mM | 407.7 μL | 2.0387 mL | 4.0775 mL | 
| 10 mM | 203.9 μL | 1.0194 mL | 2.0387 mL | 
| 第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
| 给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
| 第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
			           2.
			一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
			           3. 以上所有助溶剂都可在 GlpBio 网站选购。
			
Quality Control & SDS
- View current batch:
- Purity: >99.50% 
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
 
 
   
   
   
  














